Jodi L. Taraba

Safety, efficacy, and tolerability of systemic therapies in male breast cancer: are there sex-specific differences?

R. Leon-Ferre, K. Ruddy, Karthik V. Giridhar, 2020, Expert opinion on drug safety.

Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study.

Joseph A. Sutton, Krishna R. Kalari, Sebastian M. Armasu, 2022, Genetics in medicine : official journal of the American College of Medical Genetics.

Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer

L. Smith, C. Frei, L. B. Rangel, 2014, Breast Cancer Research and Treatment.

Risk of relapse in patients receiving azithromycin after allogeneic HSCT

M. Patnaik, K. Mara, W. Hogan, 2020, Bone Marrow Transplantation.

Abstract PS14-06: Real-World Analysis of Adverse Events in Patients with Triple Negative Breast Cancer Receiving Therapy per KEYNOTE-522

K. Clifton, Kelsey Finch, M. Hofherr, 2024, Cancer Research.

Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic Experience.

R. Leon-Ferre, T. Haddad, T. Hobday, 2024, Clinical breast cancer.